查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1842223

卵巢癌診斷市場規模、佔有率和趨勢分析報告：按癌症類型、診斷、最終用途、地區和細分市場預測，2025-2033 年

Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), By Diagnosis (Imaging, Blood Test, Biopsy), By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

卵巢癌診斷市場摘要

預計 2024 年全球卵巢癌診斷市場價值將達到 17.4 億美元，到 2033 年將達到 31.1 億美元，2025 年至 2033 年的複合年成長率為 6.73%。

由於生物標記的發現、聯邦政府的資助和新技術，卵巢癌診斷市場正在快速發展。

預計到 2025 年，美國新患者，死亡人數超過 12,000 人，凸顯了早期發現的必要性。 PPP2R1A 突變作為卵巢透明細胞癌的預測生物標記物，AOA Dx 的多組體學人工智慧血液檢測在有症狀女性中實現了 90% 以上的準確率，超過了傳統的生物標記。聯邦政府的支持力道很大，國防部在 2025 財政年度為其卵巢癌研究計畫撥款 6.5 億美元，用於資助精準醫療、預防和生存研究。儘管取得了進展，但檢測差距仍然存在，尤其是在老年和服務不足的女性中。總體而言，市場正在轉向高精度、多體學和以患者為中心的診斷，提供了巨大的成長潛力。

卵巢癌診斷市場正在經歷重大變革，其影響​​因素包括流行病學需求、生物標記的發現、技術創新以及臨床策略的轉變。根據美國 Cancer Society) 統計，2025 年美國將新增 20,890 例卵巢癌病例，其中 12,730 例死亡。儘管卵巢癌是女性第 11 大常見癌症，但它是癌症相關死亡的第五大原因，也是最致命的婦科惡性腫瘤。截至 2022 年，美國約有 243,572 名女性被診斷出患有卵巢癌 (SEER)，這表明越來越多的患者群體依賴早期精準診斷。值得注意的是，雖然卵巢癌死亡率正在緩慢下降，但其進展仍落後於其他癌症的治療水平，這凸顯了開發更完善的檢測和分層工具的緊迫性。

市場正日益受到生物標記主導的創新的影響。 MD 安德森癌症中心於2025年7月取得一項突破性發現，該發現將PPP2R1A突變作為預測卵巢透明細胞癌（OCCC）免疫治療患者生存期延長的生物標記，使中位總生存期延長至66.9個月，而未攜帶該突變的患者僅為9.2個月。這項突破性成果證明了免疫基因組學診斷的有效性，凸顯了基因檢測在患者分層中的作用，並刺激了對下一代分子診斷的需求。同時，早期臨床試驗正在探索OCCC和其他腫瘤類型的治療靶點，重點關注PP2A通路，展現了診斷和治療如何在精準腫瘤學框架下緊密結合。

與此同時，重大資助計劃正在積聚勢頭。 2025年4月，美國國防部（DoD）累計為國會指導的醫學研究計畫（CDMRP）撥款6.5億美元，其中一部分將分配給卵巢癌研究計畫（OCRP）。 2025會計年度的OCRP將支持早期檢測、預防、生存和精準醫療領域的高影響力研究，主要津貼包括研究者主導研究獎（最高105萬美元）、臨床試驗學院早期職業研究者獎（最高140萬美元）以及試點獎（最高35萬美元）。這些投資彰顯了聯邦政府對加速診斷創新和改善臨床療效的堅定承諾。

儘管取得了進展，但檢測差距仍然是一個重要的市場促進因素。 2025年3月，卵巢癌研究聯盟 (OCRA) 和科莫多健康組織 (Komodo Health) 報告稱，儘管有普遍適用的指南，但仍約有一半的卵巢癌女性未接受基因檢測。這種差距在65歲以上和用戶公共保險的女性中最為明顯，她們的檢測率低於40%。解決這些差距對於改善治療效果至關重要，因為基因檢測是治療方案的基礎，尤其是對於符合PARP抑制劑治療條件的BRCA突變患者。因此，像OCRA這樣的組織正在擴展患者支援工具，例如其「尋找醫生」平台（於2024年4月上線），該平台將患者與2000多名婦科腫瘤科醫生聯繫起來，並整合了臨床試驗搜尋功能，以提高診斷意識和採用率。

市場也受益於預防策略的策略性調整：根據英國一項大型臨床試驗的證據表明，基於症狀的檢測對死亡率的影響有限，OCRA 和婦科腫瘤學會 (SGO) 已開始倡導在 2023 年進行普遍基因檢測和機會性切除術（在盆腔手術期間切除術輸卵管）。這種轉變反映出人們越來越依賴基於風險的診斷和基因診斷而不是傳統的篩檢，並正在推動分子和基因組檢測的廣泛應用。

技術突破也在重新定義早期檢測。 2025年8月，AOA Dx在《癌症研究通訊》上發表了同行評審結果，顯示其基於人工智慧的多組體學血液檢測在有症狀的女性中實現了高準確率，在訓練隊列中，所有分期卵巢癌的AUC為93%，早期卵巢癌的AUC為91%，而在獨立的現實世界隊列中，AUC892%和2%2%。該平台將脂質、神經節苷脂和蛋白質生物標記與機器學習相結合，提供了一種可擴展的非侵入性解決方案，超越了傳統的生物標記。

此外，像OCRA的國際資料共享中心和首個卵巢和子宮內膜癌登記處（2023年）這樣的舉措正在建構大規模真實世界證據生成的基礎設施。透過整合患者層面的基因組和臨床數據，這些努力旨在加速生物標記的發現，改善預測性診斷，並促進支付者採用，而這正是診斷行業日益重要的成長槓桿。

總體而言，卵巢癌診斷市場正迅速從傳統的病理和症狀識別轉向基因組學主導、精準主導和以患者為中心的模式。成長的驅動力來自多種因素，包括盛行率的上升、PPP2R1A 等突破性生物標記、對公平獲取基因檢測的需求、數位化患者導航工具的整合、強大的聯邦研究資金以及數據主導研究的國際合作。儘管檢測差異、成本障礙以及缺乏有效的早期篩檢工具等挑戰仍然存在，但該領域正在發展成為更廣泛的下一代癌症診斷市場中的一個高價值細分領域。伴隨診斷、液態切片創新和免疫基因組學檢測正日益決定其發展軌跡，預計未來十年將釋放巨大的商業性和臨床機會。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章卵巢癌診斷市場變數、趨勢和範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 卵巢癌診斷市場分析工具
    • 波特分析
    • PESTEL分析

第4章卵巢癌診斷市場：癌症估計與趨勢分析

  • 細分儀表板
  • 卵巢癌診斷市場：癌症變異分析（2024 年和 2033 年）
  • 上皮腫瘤
  • 生殖細胞腫瘤
  • 基質細胞腫瘤
  • 其他

第5章卵巢癌診斷市場：診斷評估與趨勢分析

  • 細分儀表板
  • 卵巢癌診斷市場：診斷變異分析（2024 年和 2033 年）
  • 影像
  • 血液檢查
  • 切片檢查
  • 其他

第6章卵巢癌診斷市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 卵巢癌診斷市場：2024 年和 2033 年最終用途變化分析
  • 醫院檢查室
  • 癌症診斷中心
  • 研究所
  • 其他

第7章卵巢癌診斷市場：區域估計與趨勢分析

  • 2024年及2033年卵巢癌診斷市佔率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • F. Hoffmann-La Roche AG
    • Johnson &Johnson Services, Inc.
    • GlaxoSmithKline Plc
    • AstraZeneca Plc
    • Siemens Healthcare GmbH
    • Abbott
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc
    • Quest Diagnostics Incorporated
    • Illumina, Inc
Product Code: GVR-3-68038-421-5

Ovarian Cancer Diagnostics Market Summary

The global ovarian cancer diagnostics market size was estimated at USD 1.74 billion in 2024 and is projected to reach USD 3.11 billion by 2033, growing at a CAGR of 6.73% from 2025 to 2033. The ovarian cancer diagnostics market is advancing rapidly, driven by biomarker discovery, federal funding, and new technologies.

In 2025, the U.S. will see nearly 21,000 new cases and over 12,000 deaths, underscoring the need for earlier detection. Breakthroughs include PPP2R1A mutations as predictive biomarkers in ovarian clear cell carcinoma and AOA Dx's multi-omic, AI-powered blood test, which achieved >90% accuracy in symptomatic women, outperforming traditional biomarkers. Federal support is strong, with the DoD allocating $650M in FY25 to the Ovarian Cancer Research Program, funding precision medicine, prevention, and survivorship studies. Despite progress, testing disparities persist, particularly in older and underserved women. Overall, the market is shifting toward precision, multi-omic, and patient-centric diagnostics with significant growth potential.

The ovarian cancer diagnostics market is significantly transforming, shaped by epidemiological need, biomarker discovery, technological innovation, and shifting clinical strategies. In 2025, an estimated 20,890 new cases of ovarian cancer will be diagnosed in the U.S., with 12,730 deaths (American Cancer Society). Despite being the 11th most common cancer among women, ovarian cancer remains the fifth leading cause of cancer-related death and the deadliest gynecologic malignancy. As of 2022, approximately 243,572 women in the U.S. were living with a prior ovarian cancer diagnosis (SEER), reflecting the growing patient base that depends on early and accurate diagnostics. Significantly, mortality rates are modestly declining but lag behind improvements seen in other cancers, highlighting the urgency for better detection and stratification tools.

The market is increasingly shaped by biomarker-driven innovation. A landmark discovery in July 2025 at MD Anderson Cancer Center identified PPP2R1A mutations as a predictive biomarker for improved survival in ovarian clear cell carcinoma (OCCC) treated with immunotherapy, with median overall survival extending to 66.9 months versus 9.2 months in non-mutant patients. This breakthrough validates immunogenomic diagnostics and highlights the role of genetic testing in patient stratification, fueling demand for next-generation molecular diagnostics. Parallel efforts focus on the PP2A pathway, with early-phase trials exploring therapeutic targeting in OCCC and other tumor types, demonstrating how diagnostics and therapeutics converge in a precision oncology framework.

In parallel, large-scale funding initiatives are reinforcing this momentum. In April 2025, the U.S. Department of Defense (DoD) announced $650 million in appropriations for its Congressionally Directed Medical Research Programs (CDMRP), with a dedicated portion for the Ovarian Cancer Research Program (OCRP). The FY25 OCRP will support high-impact research on early detection, prevention, survivorship, and precision medicine, offering major grants such as the Investigator-Initiated Research Award (up to $1.05M), the Clinical Trial Academy - Early Career Investigator Award (up to $1.4M), and Pilot Awards (up to $350K). These investments signal strong federal backing to accelerate diagnostic innovation and improve clinical outcomes.

Despite advances, testing gaps remain a significant market driver. In March 2025, the Ovarian Cancer Research Alliance (OCRA) and Komodo Health reported that nearly half of women with ovarian cancer are not receiving genetic testing, despite universal guidelines. Disparities are most evident among women over 65 and those on public insurance, where testing rates fall below 40%. Since genetic testing underpins therapy selection particularly for BRCA mutation-positive patients eligible for PARP inhibitors addressing these gaps is central to improving outcomes. As a result, organizations like OCRA are expanding patient-support tools, such as the "Find a Doctor" platform (launched April 2024), which connects patients to more than 2,000 gynecologic oncology specialists and integrates trial-finder functionality, increasing awareness and adoption of diagnostics.

The market also benefits from strategic realignment in preventive strategies. Following evidence from large-scale UK trials showing the limited impact of symptom-based detection on mortality, OCRA and the Society of Gynecologic Oncology (SGO) began advocating for universal genetic testing and opportunistic salpingectomy (fallopian tube removal during pelvic surgery) in 2023. This shift reflects a growing reliance on risk-based and genetic diagnostics rather than conventional screening, driving greater uptake of molecular and genomic tests.

Technological breakthroughs are also redefining early detection. In August 2025, AOA Dx published peer-reviewed results in Cancer Research Communications showing that its multi-omic, AI-powered blood test achieved strong accuracy in symptomatic women, with an AUC of 93% for all stages and 91% for early-stage ovarian cancer in training cohorts, and 92% and 88% respectively, in independent real-world cohorts. The platform outperformed traditional biomarkers by combining lipid, ganglioside, and protein biomarkers with machine learning, offering a scalable, non-invasive solution that could transform early-stage detection, where survival benefits are most significant.

Furthermore, initiatives such as OCRA's international data commons and the first ovarian ad endometrial cancer registry (2023) create the infrastructure for large-scale real-world evidence generation. By consolidating patient-level genomic and clinical data, these efforts aim to accelerate biomarker discovery, improve predictive diagnostics, and inform payor adoption an increasingly important growth lever for the diagnostics industry.

Overall, the ovarian cancer diagnostics market moves rapidly from traditional pathology and symptom awareness toward a genomics-led, precision-driven, patient-centered model. Growth is fueled by a convergence of factors: rising disease prevalence, breakthrough biomarkers such as PPP2R1A, demand for equitable access to genetic testing, integration of digital patient navigation tools, robust federal research funding, and international collaboration in data-driven research. While challenges around testing disparities, cost barriers, and lack of validated early screening tools persist, the sector is evolving into a high-value segment of the broader next-generation cancer diagnostics market. Its trajectory is increasingly defined by companion diagnostics, liquid biopsy innovations, and immunogenomic testing, which are expected to unlock significant commercial and clinical opportunities over the next decade.

Global Ovarian Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ovarian cancer diagnostics market report based on cancer, diagnosis, end-use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Others
  • Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
    • Ultrasound
    • CT Scan
    • MRI Scan
    • PET Scan
    • Others
  • Blood Test
    • CA125
    • HER2
    • BRCA
    • CEA
    • ER & PR
    • KRAS Mutation
    • Others
  • Biopsy
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • UAE
    • South Arabia
    • South Africa
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Ovarian Cancer Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Ovarian Cancer Diagnostics Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Ovarian Cancer Diagnostics Market: Cancer Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Epithelial Tumor
    • 4.3.1. Epithelial Tumor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Germ Cell Tumor
    • 4.4.1. Germ Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Stromal Cell Tumor
    • 4.5.1. Stromal Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ovarian Cancer Diagnostics Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Ovarian Cancer Diagnostics Market: Diagnosis Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. Imaging
    • 5.3.1. Imaging Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Blood Test
    • 5.4.1. Blood Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biopsy
    • 5.5.1. Biopsy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ovarian Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Ovarian Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Hospital Laboratories
    • 6.3.1. Hospital Laboratories Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Cancer Diagnostic Centers
    • 6.4.1. Cancer Diagnostic Centers Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Research Institutes
    • 6.5.1. Research Institutes Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ovarian Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Ovarian Cancer Diagnostics Market Share, By Region, 2024 & 2033 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. South Africa
      • 7.6.3.1. South Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GlaxoSmithKline Plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. AstraZeneca Plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Siemens Healthcare GmbH
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Abbott
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Thermo Fisher Scientific
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Bio-Rad Laboratories, Inc
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Quest Diagnostics Incorporated
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Illumina, Inc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Ovarian Cancer Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 5 Global Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 6 Global Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 7 Global Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 9 North America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 10 North America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 11 North America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 13 U.S. Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 14 U.S. Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15 Canada Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 16 Canada Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 17 Canada Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18 Mexico Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 19 Mexico Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 20 Mexico Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Europe Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 22 Europe Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 23 Europe Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 24 Europe Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 UK Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 26 UK Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 27 UK Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28 Germany Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 29 Germany Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 30 Germany Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 31 France Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 32 France Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 33 France Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Spain Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 35 Spain Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 36 Spain Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37 Italy Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 38 Italy Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 39 Italy Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 40 Denmark Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 41 Denmark Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 42 Denmark Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43 Sweden Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 44 Sweden Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 45 Sweden Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Norway Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 47 Norway Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 48 Norway Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 50 Asia Pacific Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 54 Japan Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 55 Japan Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56 China Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 57 China Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 58 China Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59 Australia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 60 Australia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 61 Australia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Thailand Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 63 Thailand Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 64 Thailand Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65 India Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 66 India Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 67 India Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 68 South Korea Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 69 South Korea Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 70 South Korea Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 Latin America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 72 Latin America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 73 Latin America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 74 Latin America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 Brazil Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 76 Brazil Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 77 Brazil Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 78 Argentina Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 79 Argentina Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 80 Argentina Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 81 MEA Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 82 MEA Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 83 MEA Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 84 MEA Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 85 South Africa Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 86 South Africa Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 87 South Africa Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 UAE Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 92 UAE Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 93 UAE Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ovarian cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Ovarian cancer diagnostics market snapshot
  • Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD Million)
  • Fig. 11 Market Dynamics
  • Fig. 12 Ovarian cancer diagnostics market driver impact
  • Fig. 13 Ovarian cancer diagnostics market restraint impact
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ovarian cancer diagnostics market: Diagnosis outlook and key takeaways
  • Fig. 16 Imaging market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Blood test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Biopsy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Ovarian cancer diagnostics market : Cancer outlook and key takeaways
  • Fig. 21 Ovarian cancer diagnostics market: Cancer movement analysis
  • Fig. 22 Epithelial tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Germ cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Stromal cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Ovarian cancer diagnostics market : End Use outlook and key takeaways
  • Fig. 27 Ovarian cancer diagnostics market: End Use movement analysis
  • Fig. 28 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Cancer diagnostic centers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Research institutes market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Ovarian Cancer Diagnostics Market: Regional outlook and key takeaways
  • Fig. 33 Ovarian Cancer Diagnostics Market: Regional movement analysis
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico
  • Fig. 41 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Italy
  • Fig. 53 Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Japan
  • Fig. 63 Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 China
  • Fig. 65 China. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Thailad
  • Fig. 69 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Australia
  • Fig. 71 Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea
  • Fig. 73 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina
  • Fig. 79 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 80 MEA
  • Fig. 81 MEA market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa
  • Fig. 83 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia
  • Fig. 85 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 UAE
  • Fig. 87 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait
  • Fig. 89 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 Ansoff Matrix
  • Fig. 91 Strategy mapping
  • Fig. 92 Company market share analysis, 2022
  • Fig. 93 Heat Map Analysis
  • Fig. 94 Market differentiators
  • Fig. 95 Heat Map Analysis